darolutamide
bayer,orion corp
['darolutamide', 'dasl-hicap', 'prostate']
dasl-hicap: darolutamide augments standard therapy for localized very high-risk cancer of the #prostate (anzup1801) a randomized phase 3, double-blind, pbo-controlled trial of adding daro to adt and definitive. presented by &gt; #asco22 
Largest global online community of #urological medical professionals & patients. #AUA22 #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology